ArticlePloS one2026
Favorable association between early initiation of sodium-glucose cotransporter-2 inhibitors and in-hospital prognosis in acute myocardial infarction.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute myocardial infarction remains a major cause of death and disability worldwide, especially in low- and middle-income countries. Standard early management includes dual antiplatelet therapy, statins, beta-blockers (BB) and renin-angiotensin-aldosterone inhibitors (ACEi/ARB/MRA). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been associated with favorable changes in cardiac function in acute myocardial infarction, but their impact on in-hospital mortality has not been well established.
objectiveTo assess the association between early initiation of SGLT2i and in-hospital mortality among patients with acute myocardial infarction.
methodsA retrospective, single-center study was conducted on 394 adult patients hospitalized with acute myocardial infarction at Nguyen Trai Hospital, Ho Chi Minh City, between January 2022 and October 2024. The data extraction and analysis were performed from July 31 to October 24, 2024. Patients with incomplete data, secondary acute myocardial infarction, or eGFR < 20 mL/min/1.73 m2 were excluded. Data from electronic medical records were analyzed. The primary outcome was in-hospital mortality. Logistic regression was used to identify independent predictors.
resultsMean age was 66.0 ± 11.7 years; 57.1% were male. SGLT2i was initiated within 24 hours of admission in 23.9% of patients. In-hospital mortality occurred in 53 patients (13.5%). In multivariable analysis, lower left ventricular ejection fraction (OR 0.91, 95% CI: 0.85-0.97; p = 0.003) and sepsis (OR 5.14, 95% CI: 1.04-25.36; p = 0.04) were independently associated with in-hospital mortality. In addition, use of BB/ACEi/ARB/MRA and early SGLT2i initiation were independently associated with lower in-hospital mortality (OR 0.12, 95% CI: 0.05-0.25; p < 0.001 and OR 0.27, 95% CI: 0.07-0.96; p = 0.04, respectively).
conclusionsTogether with traditional medical treatment, initiating SGLT2i within 24 hours of admission for acute myocardial infarction was independently associated with lower in-hospital mortality. These findings suggest a potential association between early SGLT2i use and improved in-hospital outcomes and warrant further investigation in prospective randomized studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.